Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17682927 | 0.81 | CYP1A2 (0.43) | KDM4EKMT2A | |
| SCHEMBL8301886 | 0.79 | — | — | |
| SCHEMBL18774638 | 0.76 | GRIN2D (0.34) | KDM4EKMT2A | |
| SCHEMBL23240873 | 0.75 | — | — | |
| SCHEMBL7806892 | 0.75 | KDM4E (0.40) | KDM4EKMT2A | |
| SCHEMBL7808381 | 0.73 | KMT2A (0.39) | KDM4EKMT2A | |
| SCHEMBL13127864 | 0.73 | KMT2A (0.39) | KDM4EKMT2A | |
| SCHEMBL6867738 | 0.70 | KDM4E (0.67) | KDM4EKMT2A | |
| SCHEMBL8199766 | 0.70 | SMN1; SMN2 (0.37) | KDM4EKMT2A | |
| SCHEMBL19369910 | 0.70 | KDM4E (0.36) | KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298225-A1 | PEPTIDE GAP JUNCTION MODULATORS | ZEALAND PHARMA A/S (DK) | 2010-11-25 | — | — | US | disclosed |
| US-20100298225-A1 | PEPTIDE GAP JUNCTION MODULATORS | ZEALAND PHARMA A/S (DK) | 2010-11-25 | — | — | US | disclosed |
| WO-2009010733-A2 | PEPTIDE GAP JUNCTION MODULATORS | ZEALAND PHARMA A/S (DK) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298225-A1 | PEPTIDE GAP JUNCTION MODULATORS | GJA1, GJB2, GAP43 | KDM4E 4810/4885KMT2A 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.